Calendario›SNY›Dupilumab · DUPILAB

Dupilumab · DUPILAB

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

Ensayo de Sanofi en Dermatitis atopica.

Más ensayos de: Dermatitis atópica.

Fase

no aplica

Estado

En marcha, sin reclutar

Participantes

303

previstos

Centros

42

Fin del objetivo primario

may 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en nov 2023.

Qué mide

Demographic characteristics of participants who receive dupilumab for AD (del registro, en inglés) (en el inicio)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06169527), actualizada en jul 2025.